First nasal spray Ebola vaccine found to ‘offer long-term protection against deadly virus’

Greetings,

First nasal spray Ebola vaccine found to ‘offer long-term protection against deadly virus’

Scientists at the University of Texas are developing the breathable vaccine
It has been shown to protect monkeys against the deadly virus
Next step is to test vaccine on humans in phase one clinical trials
Researchers said respiratory vaccine could overcome logistical problems of storing, transporting and administering injectable vaccines
By LIZZIE PARRY FOR MAILONLINE
Read more: http://www.dailymail.co.uk

A nasal spray being developed as a potential vaccine for the deadly Ebola virus has been found to be effective.
Scientists at the University of Texas discovered the breathable vaccine offers long-term protection during pre-clinical trials with monkeys.
Since the current outbreak erupted in West Africa earlier this year, almost 5,000 people have lost their lives – the majority in Sierra Leone, Liberia and Guinea.
A number of injectable experimental vaccines are being trialled in the US, UK and Mali, with plans to extend human trials into other parts of Europe, Gabon and Kenya.
A nasal spray being developed as a potential vaccine for the Ebola virus (pictured under the microscope) has been found to protect monkeys in pre-clinical trials
–
A nasal spray being developed as a potential vaccine for the Ebola virus (pictured under the microscope) has been found to protect monkeys in pre-clinical trials
There are vaccination trials ongoing in the US and UK. It is hoped the first results will be available next year
–
There are vaccination trials ongoing in the US and UK. It is hoped the first results will be available next year
But researchers in Austin, Texas, say their small pre-clinical study is the only proof to date that a single dose of a non-injectable vaccine against Ebola is long-lasting.

They claim the discovery could have ‘significant global implications in controlling future outbreaks’.
A breathable vaccine could overcome the logistical obstacles of storing, transporting and administering injectable vaccines in parts of Africa most afflicted by the virus, the researchers said.
The work will be presented tomorrow at the American Association of Pharmaceutical Scientists Annual Meeting in San Diego.
Kristina Jonsson-Schmunk, a graduate in pharmacy and professor Dr Maria Croyle, and Dr Gary Kobinger and his team at the National Microbiology Laboratory in Winnipeg, developed the vaccine over seven years.
It was found to improve survival of immunised non-human primates from 67 per cent to 100 per cent, after challenge with 1,000 plaque forming units of Ebola Zaire 150 days after immunization…..MORE HERE

Social

First nasal spray Ebola vaccine found to ‘offer long-term protection against deadly virus’